Last reviewed · How we verify
Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer
The standard treatment of local advanced cervical cancer is concurrent chemoradiotherapy. The 3 year disease free survival was about 50-70%. The distant metastasis is the main cause of failure in local advanced cervical cancer treated with 3-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT). The purpose of this study is to investigate the efficacy and tolerance of concurrent and adjuvant chemotherapy with cisplatin and docetaxel for local advanced cervical cancer. It was expected that the 3 year disease free survival would be increased by 10% with this new treatment schedule.
Details
| Lead sponsor | Air Force Military Medical University, China |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 598 |
| Start date | 2016-02 |
| Completion | 2021-02 |
Conditions
- Cervical Cancer
Interventions
- concurrent chemotherapy with cisplatin
- concurrent chemotherapy with docetaxel
- pelvic radiotherapy
- brachytherapy
- adjuvant chemotherapy with cisplatin and docetaxel
Primary outcomes
- disease free survival — 3 year
Countries
China